pgml-1, range 2.5-> 100 pg ml-') and in 67 patients with primary carcinoma (median 1.0pgml-', range 3.8->100ugml-'). Elevated Ca antigen levels were found in 50% of patients with metastatic spread (median 30.7pgmlP', range 8.2->l 00gmlP') and in some patients with primary disease but further studies are needed to determine the prognostic significance. Immunochemical studies confirmed that Ca antigen is a normal serum product but its function is unclear.
extended tests on human sera from patients with breast disease because of its greater ease and economy in use. Circulating Ca antigen was not exclusive to malignancy and the level failed to discriminate between patients with primary carcinoma and those with benign disease. Ca antigen was present in sera of 100 healthy individuals (median 7.1 pgml-', range 1.8-24.4pgml) -', 39 patients with benign disease (median 9.9 pgml-1, range 2.5-> 100 pg ml-') and in 67 patients with primary carcinoma (median 1.0pgml-', range 3.8->100ugml-'). Elevated Ca antigen levels were found in 50% of patients with metastatic spread (median 30.7pgmlP', range 8.2->l 00gmlP') and in some patients with primary disease but further studies are needed to determine the prognostic significance. Immunochemical studies confirmed that Ca antigen is a normal serum product but its function is unclear.
There is considerable interest in non-invasive techniques for the early detection of breast carcinoma. Elevated serum levels of several markers have been reported in patients with breast disease but the sensitivity and specificity of detection have been inadequate for early diagnosis (Coombes et al., 1982; Waalkes et al., 1984; Wang et al., 1984) . Polyclonal antibodies have been almost exclusively used in assays for circulating tumour-associated antigens. It is conceivable that monoclonal antibodies of restricted epitope specificity may improve diagnostic discrimination. Monoclonal Ca 1 antibody which defines a mucin type glycoprotein has been reported to react selectively in immunohistochemical studies with malignant lesions taken from a variety of tissues Woods et al., 1982) , although more recent studies have shown that reactivity is not exclusive to malignant lesions of the'breast (Simpson et al., 1983; Beckford & Chantler, 1984; Beckford et al., 1985) .
This work was undertaken to establish a simple assay for detection of Ca antigen in serum and to determine whether measurement of circulating Ca antigen would be helpful in discriminating between benign and malignant breast disease. Antigen preparations Crude Ca antigen was prepared from HEp2 cells (-5 x 106) by centrifugation, followed by washing in PBS (2 x) and extraction in 1% Triton X-100 and 10mM Tris HCI pH8 (1:lv/v) for lh at 4°C. After centrifugation at 10,000g for 30min, 1% (w/v) sodium deoxycholate was added to the supernatant. Extracts of control antigen were similarly derived from a lymphoblastoid cell line (Namalwa), known to be free of Ca antigen.
Materials and methods

Serum samples
A Assay procedures Inhibition radioimmunoassay (Inhibition-RIA) Polyvinyl microtitre wells were coated with crude Ca antigen (200 p1, diluted 1: 1,000 in PBS) and incubated for 1 h at 37°C, followed by overnight at 4°C. One hundred and twenty-five p1 of each serum sample diluted 1:5 and 1:20 in PBS, was added to an equal volume of 1251 Ca 1 antibody (250,000 c.p.m.) in 6% BSA/PBS and incubated for 2 h at room temperature (RT). The serum/tracer mixture (100 ,l containing 100,000c.p.m.) was added, in duplicate, to antigen and control antigen coated wells previously washed with 3% BSA/PBS (x3) and incubated for 2h at RT. After washing the wells (0.05% Tween/PBS x 3) the bound activity was counted. A standard curve of crude Ca antigen prepared in 20% normal mouse serum in PBS (previously calibrated against the purified Ca antigen preparation) was included in each assay and used to calculate Ca antigen levels in sera. Immunoradiometric assay (IRMA) Polystyrene tubes (6 cm x 1 cm) were coated with IgM preparations (200pl, 15 gml-' PBS) derived from Ca 1 or control IgM ascitic fluid at 4°C overnight. After washing with PBS (2mlx3), 100p1 of serum was added to duplicate tubes and left at 4°C overnight. After a further wash cycle, 100p1 of 1251 Ca 1 (100,000 c.p.m.) diluted in 3% BSA/PBS containing 10% normal mouse serum, was added. The tubes were incubated at RT for 4h, washed with PBS (2 x 3 ml) and counted. The results were read from the standard curve as described for the Inhibition RIA. Immunohistochemistry The presence of Ca antigen in paraffin wax embedded tissue sections taken from benign and malignant lesions was detected by the indirect immunoenzyme procedure described by Beckford & Chantler (1984) with the exception that alkaline phosphatase was substituted as label (Foster et al., 1982) . Identification of Ca antigen in serum Ca antigen was separated from serum by affinity chromatography using a modification of the procedure reported by Ashall et al (1982) . Fifteen ml of serum, dialysed against PBS was applied to an immunoadsorbent column (2 x 7 cm) of Sepharose 4B-Ca 1. The bound fraction, containing Ca antigen, was eluted with 3 M sodium thiocyanate (pH 7.6) in PBS, dialysed and concentrated by lyophilisation. The sample constituents were separated by SDS polyacrylamide gel electrophoresis (SDS-PAGE) and the presence of Ca antigen was detected by autoradiography or indirect immunofluorescence. Each sample was reconstituted with distilled water (100pl) and a 30,ul aliquot was reduced by boiling in 2% P-mercaptoethanol and 2% sodium dodecyl sulphate (SDS) for 5min and applied to 5% polyacrylamide gels (Laemeli, 1970) which were electrophoresed for 5 h at 40 mA. Crude Ca antigen extract was treated in the same way and included in each run. Localisation on the gels was performed by incubating with 1251 wheat germ lectin (overnight/RT) followed by dehydration and autoradiography . Alternatively the separated components were transferred to nitrocellulose (Towbin et al., 1979) before staining with Ca 1 ascitic fluid (1:30 in 3% BSA/PBS) overnight at RT followed by FITC labelled sheep anti-mouse IgM (1:20 in PBS) for 0.5 h at RT. Fluorescence was detected using an excitation wavelength of 366 nm. with the inter-assay variation obtained with quadruplicate tests performed on three occasions. The sensitivity of the Inhibition-RIA was slightly greater than IRMA, the lower limit of Ca detection lay between 100-250 ng ml-l and 250-500 ng ml-l respectively. The inter-assay variation, determined by assaying aliquots of 2 serum pools (mean values 7.1 and 13.9gml-P 1) in successive assays was 18.0% (n =14) and 10.6% (n = 15) respectively. The intra-assay variation for 24 An extended analysis was performed on the levels of Ca antigen in sera from 93 patients with malignant and 39 with benign breast disease and from 100 normal subjects, which included samples from 12 individuals with acute viral infection. All samples gave some reactivity in the assay. The range of values obtained in each group and the distribution are shown in Table I The median values 9.9 and 11.0 in the benign and primary carcinoma groups were not significantly different (P=0.26) but three patients in the latter group had highly elevated levels (58, 65.5, >100) and one of these relapsed at 2 years (>100). Other patients with known early relapse, however, had Ca values within the normal range. Although there was an overlap between the Ca values obtained in each group, the median Ca value of samples taken from patients with metastases differed significantly from that of the control and benign disease groups (P= <0.001). This was due to the high proportion of samples (13/26, 50%) with significantly elevated activity. Unfortunately it was not possible to determine whether testing of sequential samples from individual patients would be of prognostic value.
Results
Comparison
These results show that measurement of circulating Ca fails to discriminate between individuals with primary carcinoma of the breast and non-malignant conditions.
Correlation between circulating and tissue Ca antigen Sections of cancer (8 patients) and benign breast tumour (11 patients) were examined for the Identification of Ca antigen in serum Low levels of Ca activity were found in all normal serum samples. In order to confirm that this was due to the presence of Ca antigen, studies were undertaken to purify Ca antigen from three normal sera. Serum samples were partially purified by affinity chromatography on a Sepharose 4B-Ca 1. Unbound material, present in the void volume and specifically bound components, eluted with sodium thiocyanate, were tested in the Inhibition-RIA. The major proportion of the original activity was recovered in the eluate. Components in this fraction were separated by SDS polyacrylamide gel electrophoresis and the presence of Ca was demonstrated by 121I wheat germ lectin or indirect immunofluorescence. The autoradiograph obtained after treating the gels with 1251 wheat germ lectin showed that a high mol. wt component, analogous to that seen in the gel containing HEp 2 extract and exhibiting the properties of Ca antigen (Bramwell et al., 1983) , was present in samples separated from normal serum (Figure 4) . Immunofluorescence failed to give conclusive results with material isolated from normal sera but stained the 2 major high mol. wt components in the HEp 2 extract which bound 1251I wheat germ lectin. The results show that at least one of the high mol. wt components present in Ca antigen is present in normal serum. Our failure to demonstrate Ca in preparations from normal serum by immunofluorescence is likely to be due to inadequate sensitivity.
Discussion
This study shows that the presence of Ca antigen in human serum is not exclusive to malignancy and that the level of circulating Ca antigen fails to discriminate between primary carcinoma and non-malignant conditions of the breast. This observation is in agreement with the general conclusions reached in recent reviews dealing with a range of biological markers used in breast disease (Coombes et al., 1982; Waalkes et al., 1984) . Although the presence of Ca antigen in serum had no diagnostic significance, 50% of patients with metastatic spread had significantly elevated levels. The possibility that measurement of Ca levels in sequential serum samples may be of prognostic value in individual patients cannot be excluded. Similar results have been reported in a study using a polyclonal antibody in which the circulating levels of human mammary epithelial antigens (HME-Ags) in patients with breast disease were investigated (Ceriani et al., 1982 (Simpson et al., 1983; Beckford et al., 1984) . Comparison of circulating and tissue Ca antigen in individual patients performed in this study showed that Ca antigen was present in almost all' tissues irrespective of the histological classification and that an extensive tissue distribution was not associated with elevated levels of circulating antigen. In this context, it is interesting to note that circulating human milk fat globule antigens were not detected in sera from normal subjects and patients with benign breast disease by Ceriani et al. (1982) despite the presence of tissue antigen in benign lesions by immunohistochemical tests (Ceriani et al., 1979) .
A significant feature of this study was the observation that Ca antigen was present in all serum samples tested. The specificity of our assay was confirmed by the use of control antigen and antibody but definitive evidence that the active component in serum was Ca antigen was obtained by purification and immunochemical analysis. Comparison with HEp 2 extracts showed conclusively that the active component in normal sera was analogous to one of the 2 high mol. wt components of Ca antigen (Bramwell et al., 1983) . The absence of the second component is thought to be a reflection of the known polymorphism of the antigen (M. Bramwell, personal communication) .
Our studies show that Ca antigen is a normal serum product but its function has yet to be determined. The detection of circulating Ca antigen is not of diagnostic significance in breast cancer and limited analysis suggest that elevated values in primary carcinoma patients are not associated with early relapse (results not given). Further work to determine the prognostic value of circulating Ca antigen in breast disease and to investigate the applicability of our conclusions to other diseased organs is in progress.
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